Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial.
Articles > Article · 2018
Authors: Griesshammer Mİ, Güray SAYDAM, FR PALANDİRİ, Gİ BENEVOLO, MA EGYED, JE CALLUM, Tİ DEVOS, Serdar ŞIVGIN, PA GUGLİELMELLİ, CE BENSASSON, MU KHAN, JP RONJO, FR PASSAMONTİ
Ann Hematol, Journal Indexed in SCI Expanded, International, Social Sciences Citation Index, 2018, vol 98, pp 1591-1600